NASDAQ:BEAM Beam Therapeutics (BEAM) Stock Price, News & Analysis $26.33 -0.48 (-1.81%) Closing price 03:59 PM EasternExtended Trading$26.77 +0.45 (+1.70%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Beam Therapeutics Stock (NASDAQ:BEAM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Beam Therapeutics alerts:Sign Up Key Stats Today's Range$25.87▼$26.7950-Day Range$21.90▼$32.3252-Week Range$15.35▼$36.44Volume1.49 million shsAverage Volume2.04 million shsMarket Capitalization$2.71 billionP/E RatioN/ADividend YieldN/APrice Target$46.83Consensus RatingModerate Buy Company Overview Beam Therapeutics, Inc. (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need. Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R. Liu, Ph.D., and a team of genome-editing pioneers. Unlike traditional CRISPR/Cas9 approaches that create double-strand DNA breaks, Beam’s base editing platform converts one DNA letter into another through targeted enzymatic reactions, minimizing genomic disruption. The company’s pipeline includes ex vivo programs for monogenic blood disorders such as sickle cell disease and beta thalassemia, as well as in vivo candidates aimed at rare metabolic and genetic conditions. Strategic collaborations with major pharmaceutical partners support the translation of these programs into clinical development. Since its initial public offering in early 2020, Beam Therapeutics has expanded its capabilities in research, development and manufacturing, forging partnerships to scale delivery and production of its novel editors. The company’s leadership team brings together seasoned executives and scientists with expertise in protein engineering, lipid nanoparticle delivery and regulatory strategy, all united by a commitment to advance next-generation precision therapies. As Beam progresses key programs toward clinical milestones, it remains focused on translating base editing innovations into safe and effective treatments for patients worldwide.AI Generated. May Contain Errors. Read More Beam Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreBEAM MarketRank™: Beam Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 228th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBeam Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 9 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialBeam Therapeutics has a consensus price target of $46.83, representing about 77.9% upside from its current price of $26.33.Amount of Analyst CoverageBeam Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Beam Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Beam Therapeutics are expected to grow in the coming year, from ($4.23) to ($3.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -38.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -38.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Beam Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted21.15% of the float of Beam Therapeutics has been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 9.51.Change versus previous monthShort interest in Beam Therapeutics has recently decreased by 5.78%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment-0.40 News SentimentBeam Therapeutics has a news sentiment score of -0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Beam Therapeutics this week, compared to 5 articles on an average week.Search Interest29 people have searched for BEAM on MarketBeat in the last 30 days. This is an increase of 81% compared to the previous 30 days.MarketBeat Follows12 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,899,942.00 in company stock.Percentage Held by Insiders3.80% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Beam Therapeutics' insider trading history. Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BEAM Stock News HeadlinesBeam Therapeutics Data Puts BEAM 302 And AAT Disease In FocusMay 19 at 8:01 AM | finance.yahoo.comHedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?May 18 at 12:56 AM | finance.yahoo.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 19 at 1:00 AM | Paradigm Press (Ad)Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 ...May 18 at 12:56 AM | markets.businessinsider.comBeam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International ConferenceMay 18 at 4:00 PM | globenewswire.comBeam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1May 13, 2026 | prnewswire.comBeam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset StoryMay 13, 2026 | seekingalpha.com3 Biotech Stocks That Could Benefit from the Patent Cliff (BEAM)Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets...April 27, 2026 | marketbeat.comSee More Headlines BEAM Stock Analysis - Frequently Asked Questions How have BEAM shares performed this year? Beam Therapeutics' stock was trading at $27.72 at the beginning of 2026. Since then, BEAM shares have decreased by 5.0% and is now trading at $26.3260. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.12. The company's revenue for the quarter was up 323.2% compared to the same quarter last year. Does Beam Therapeutics have any subsidiaries? Beam Therapeutics subsidiaries include Blink Therapeutics Inc.. When did Beam Therapeutics IPO? Beam Therapeutics (BEAM) raised $169 million in an IPO on Thursday, February 6th 2020. The company issued 10,588,236 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Beam Therapeutics' major shareholders? Top institutional shareholders of Beam Therapeutics include Sumitomo Mitsui Trust Group Inc. (3.72%), Amova Asset Management Americas Inc. (3.72%), Dimensional Fund Advisors LP (2.10%) and ADAR1 Capital Management LLC (1.41%). Insiders that own company stock include John M Evans, Giuseppe Ciaramella, Christine Bellon, Amy Simon, Terry-Ann Burrell, Bethany J Cavanagh and Fmr Llc. View institutional ownership trends. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Beam Therapeutics investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW), McKesson (MCK) and Yum! Brands (YUM). Company Calendar Last Earnings5/07/2026Today5/19/2026RBC Capital Markets Global Healthcare Conference 20265/20/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BEAM's financial health is in the Green zone, according to TradeSmith. BEAM has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BEAM CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees510Year Founded2017Price Target and Rating Average Price Target for Beam Therapeutics$46.83 High Price Target$80.00 Low Price Target$21.00 Potential Upside/Downside+77.9%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.99 million Net Margins-39.66% Pretax Margin-40.23% Return on Equity-29.00% Return on Assets-22.61% Debt Debt-to-Equity Ratio0.09 Current Ratio16.99 Quick Ratio16.99 Sales & Book Value Annual Sales$139.74 million Price / Sales19.38 Cash FlowN/A Price / Cash FlowN/A Book Value$12.20 per share Price / Book2.16Miscellaneous Outstanding Shares102,880,000Free Float98,970,000Market Cap$2.71 billion OptionableOptionable Beta2.26 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:BEAM) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
